Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 69.54M shares rose 10.6% year over year, ahead of the +7.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 10.4% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.6% holds above the trailing-twelve-month pace of +7.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 62.98M USD
- Year-over-year change
- +14.7%
- 4-year CAGR
- +14.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.98M | +14.7% |
| FY2024 | 2024-12-31 | 54.9M | +30.8% |
| FY2023 | 2023-12-31 | 41.97M | +0.9% |
| FY2022 | 2022-12-31 | 41.59M | +11.9% |
| FY2021 | 2021-12-31 | 37.17M | — |
Weighted Avg Shares vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 weighted avg shares of 64.63M shares is the 3rd highest of the 11 companies compared; the peer median is 41.21M shares.
- Its year-over-year change of +7.9% is the 5th highest of 11, against a peer median of +4.4%.
- Over three fiscal years its annual growth of +14.8% compares with a peer median of +14.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 167.44M | +37.1% | +15.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | 98.81M | +34.9% | +76.1% |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
| LTM Mar 2026 | 59.11M | +1.3% | +1.4% | |
| LTM Mar 2026 | 41.5M | +5.9% | +9.8% | |
| LTM Mar 2026 | 40.92M | +29.8% | +18.6% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | 32.39M | +0.9% | +13.4% |
| LTM Mar 2026 | 27.53M | +1.8% | +1.2% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| LTM Mar 2026 | 10.86M | +66.5% | +40.6% | |
| Peer median (excluding FHTX) | 41.21M | +4.4% | +14.4% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.